Catalyst
Slingshot members are tracking this event:
Recro (REPH) to Complete Enrollment for 700 Patient Safety Study of IV Meloxicam by Q1 or Early Q2
- Source Link:
- http://seekingalpha.com/filings/pdf/11772280.pdf
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REPH |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2017
Occurred Source:
http://ir.recropharma.com/press-releases/detail/62/recro-pharma-completes-enrollment-in-phase-iii-safety-study
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Enrollment, Iv Meloxicam
